Key result
Drug-coated balloons showed no significant difference in the risk of major adverse cardiac events compared to drug-eluting stents in patients with small coronary artery disease.
Why the study?
Although drug-coated balloons show promising results in large coronary artery lesions, their efficacy and safety in patients with small coronary artery disease remain not well established.
Does drug-coated balloons reduce MACE in patients with small coronary artery disease compared to drug-eluting stents?
Meta-Analysis (n=18,469)
Does drug-coated balloons reduce MACE in patients with small coronary artery disease compared to drug-eluting stents?
In patients with small coronary artery disease, drug-coated balloons are a viable alternative to drug-eluting stents, showing comparable rates of MACE but significantly decreased mean lumen diameter and net luminal gain.
Answers are grounded in this paper and cite their sources.
DCB yields comparable MACE rates to DES in small CAD; leaves open questions on higher restenosis pending randomized trials.
BACKGROUND: Drug-coated balloons (DCB) have promising results in the management of large coronary artery lesions (CAD), still their role in treating small CAD is not well established. We aimed to provide a comprehensive appraisal of the efficacy and safety of DCBs in patients with small CAD. METHODS: We searched PubMed, Scopus, web of science, Ovid, and Cochrane Central from inception until 30 March, 2023. We included all relevant studies that compared DCB versus drug-eluting stents (DES) in small CAD patients undergoing PCI. We reported clinical outcomes as MACE, all-cause death, cardiac death, MI, TLR, TVR, and stent thrombosis, while angiographic outcomes were late lumen loss (LLL), mean lumen diameter (MLD), net luminal gain (NLG), and in-segment binary restenosis. RESULTS: Twenty studies comprising 18,469 patients were included in this meta-analysis. The incidence rate of MACE was 9.4% in the DCB group compared to 9.9% in the DES group, without a significant difference in the risk of MACE (OR = 0.97, 95% CI: 0.77 to 1.22, p = 0.78). Moreover, DCB significantly decreased MLD and NLG compared to DES, with the following values, respectively (MD= -0.19, 95% CI: -0.32 to -0.06, p < 0.001, and MD -0.21, 95% CI: -0.40 to -0.01, p = 0.04). On the other hand, DCB was associated with higher odds in the risk of in-segment binary restenosis (OR 1.66, 95% CI: 1.03 to 2.68, p = 0.04). CONCLUSION: DCB is an alternative approach to DES in the management of small CAD and should be validated in daily clinical practice. PROSPERO REGISTRATION: CRD42023413068.
No takes yet. Share an insight, caveat, or question.
Abdelaziz et al. (2025) conducted a meta-analysis in Small coronary artery disease (n=18,469). Drug-coated balloons vs. Drug-eluting stents was evaluated on Major Adverse Cardiac Events (MACE) (OR 0.97, 95% CI 0.77 to 1.22, p=0.78). Drug-coated balloons showed no significant difference in the risk of major adverse cardiac events compared to drug-eluting stents in patients with small coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: